Statera Biopharma, Inc.

OTCPK:STAB Stock Report

Market Cap: US$7.3k

Statera Biopharma Balance Sheet Health

Financial Health criteria checks 0/6

Insufficient data to determine the health of Statera Biopharma

Key information

n/a

Debt to equity ratio

n/a

Debt

Interest coverage ration/a
Cashn/a
Equityn/a
Total liabilitiesn/a
Total assetsn/a

Recent financial health updates

Recent updates

Statera Biopharma updates on Nasdaq Listing Status

Sep 12

Statera Biopharma gets anticipated notice of additional filing delinquency from Nasdaq

Aug 25

In this section we usually analyse Statera Biopharma's finance health to determine how well-positioned it is against times of financial distress, in particular, its ability to manage its cash and debt levels. Statera Biopharma has not provided adequate balance sheet data, its financial health cannot be properly assessed as it.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have financial information.

Financial Position Analysis

Short Term Liabilities: Insufficient data to determine if STAB's short term assets cover its short term liabilities.

Long Term Liabilities: Insufficient data to determine if STAB's short term assets cover its long term liabilities.


Debt to Equity History and Analysis

Debt Level: Insufficient data to calculate STAB's net debt to equity ratio to determine if it is satisfactory.

Reducing Debt: Insufficient data to determine if STAB's debt to equity ratio has reduced over the past 5 years.

Debt Coverage: Insufficient data to determine if STAB's debt is well covered by operating cash flow.

Interest Coverage: Insufficient data to determine if STAB's interest payments on its debt are well covered by EBIT.


Balance Sheet


Discover healthy companies